Clinical Trial Update: A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY) [Phase 2]

View source ↗

Summary

Phase 2 open-label pilot study of soticlestat in Duplication 15q and CDKL5 deficiency disorder has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• 15q Duplication Syndrome
• Cdkl5 Deficiency Disorder

Drugs mentioned

• Soticlestat (TAK-935/OV935) (soticlestat)

Snippet

Sponsor: Takeda | Conditions: 15q Duplication Syndrome, CDKL5 Deficiency Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-04-20